HUTCHMED Divests 45% Stake in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals Holding
January 3, 2025
HUTCHMED agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for about US$608 million in cash to GP Health Service Capital Co. and Shanghai Pharmaceuticals Holding. The divestment allows HUTCHMED to reallocate capital to its core oncology and ATTC (antibody-targeted therapy conjugate) pipeline and accelerate its path to profitability.
- Buyers
- GP Health Service Capital Co., Shanghai Pharmaceuticals Holding Co., Ltd.
- Targets
- Shanghai Hutchison Pharmaceuticals Limited (SHPL)
- Sellers
- HUTCHMED
- Industry
- Pharmaceuticals
- Location
- Shanghai, China
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
PureHealth Acquires 60% Stake in Hellenic Healthcare Group
October 7, 2025
Healthcare Services
PureHealth Holding PJSC agreed to acquire a 60% stake in Hellenic Healthcare Group (HHG), valuing HHG at about USD 2.3 billion. The acquisition integrates HHG’s hospital and diagnostic-centre footprint in Greece and Cyprus into PureHealth’s global healthcare platform.
-
Lakeside Holding Acquires Hupan Pharmaceutical (Hubei) to Enter Medical Logistics in China
November 11, 2024
Healthcare Services
Lakeside Holding Limited, through its wholly owned subsidiary Sichuan Hupan, entered into an equity transfer agreement to acquire Hupan Pharmaceutical (Hubei) Co., Ltd. for RMB 4.0 million (US$0.6 million). The acquisition is expected to add approximately US$7 million in annual revenue and expands Lakeside’s capabilities into China’s medical logistics sector.
-
SHS Capital and LPs Invest ~€10M in Develco Pharma
October 7, 2024
Pharmaceuticals
SHS Capital, together with its limited partners and other existing shareholders, is investing approximately €10 million in Develco Pharma to expand manufacturing capacity and accelerate product development in response to exceptionally strong demand. Develco, a specialty pharma developer and manufacturer of modified-release formulations headquartered in Pratteln (DACH region), has been backed by SHS since 2020 and reports an order book exceeding 12 months of revenue.
-
Everstone Capital Acquires Controlling Stake in Softgel Healthcare
September 14, 2022
Pharmaceuticals
Everstone Capital has acquired a controlling (majority) stake in Softgel Healthcare Private Limited (SHPL), a Chennai-headquartered CDMO specializing in soft gelatin capsules and probiotics and part of the Madras Pharma Group. The investment will support SHPL's global expansion and capability development across pharmaceutical, nutraceutical and OTC markets, with Everstone partners joining the company's board.
-
Hikma Pharmaceuticals Acquires Custopharm from Water Street Healthcare Partners
September 27, 2021
Pharmaceuticals
Hikma Pharmaceuticals has agreed to acquire Custopharm Inc., a US-based generic sterile injectables company, from Water Street Healthcare Partners for an initial $375 million plus up to $50 million in contingent consideration. The acquisition adds Custopharm's 13 approved products, R&D capabilities and pipeline to Hikma's injectables franchise and is expected to be accretive to Hikma's Injectables operating margin.
-
SHS Invests in Develco Pharma
December 17, 2020
Pharmaceuticals
Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH is making a minority growth investment from its SHS V fund in Swiss-German specialty drug company Develco Pharma. Develco, headquartered in Pratteln, Switzerland with ~125 employees and production in Schopfheim, Germany, develops and manufactures orally administered prolonged-release medicines and will use the investment to broaden its pipeline and expand capabilities.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.